Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GCVRZ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GCVRZMichael Price 2016-03-31 Add0.03%$0.08 - $0.16
($0.11)
$ 0.2191%Add 111.18%3,583,668
GCVRZMario Gabelli 2016-03-31 Reduce$0.08 - $0.16
($0.11)
$ 0.2191%Reduce -1.21%65,100
GCVRZMichael Price 2015-12-31 Add$0.1 - $0.2
($0.14)
$ 0.2150%Add 28.26%1,696,993
GCVRZMario Gabelli 2015-12-31 Reduce$0.1 - $0.2
($0.14)
$ 0.2150%Reduce -8.34%65,900
GCVRZMario Gabelli 2015-09-30 Reduce$0.19 - $0.72
($0.34)
$ 0.21-38%Reduce -0.28%71,900
GCVRZMichael Price 2015-09-30 Add$0.19 - $0.72
($0.34)
$ 0.21-38%Add 3.77%1,323,043
GCVRZMario Gabelli 2015-06-30 Reduce$0.63 - $0.75
($0.69)
$ 0.21-70%Reduce -3.13%72,100
GCVRZMario Gabelli 2015-03-31 Reduce$0.6 - $0.81
($0.7)
$ 0.21-70%Reduce -58.50%74,431
GCVRZMario Gabelli 2014-12-31 Reduce$0.47 - $0.87
($0.61)
$ 0.21-66%Reduce -40.88%179,351
GCVRZFirst Eagle Investment 2014-12-31 Reduce$0.47 - $0.87
($0.61)
$ 0.21-66%Reduce -35.34%146,402
GCVRZMichael Price 2014-09-30 Reduce-0.24%$0.45 - $0.51
($0.49)
$ 0.21-57%Reduce -75.83%1,275,000
GCVRZMario Gabelli 2014-09-30 Reduce$0.45 - $0.51
($0.49)
$ 0.21-57%Reduce -45.86%303,351
GCVRZMario Gabelli 2014-03-31 Reduce$0.3 - $0.47
($0.37)
$ 0.21-43%Reduce -35.10%631,351
GCVRZMichael Price 2013-12-31 Add0.06%$0.32 - $2.04
($1.21)
$ 0.21-83%Add 31.68%5,300,000
GCVRZFirst Eagle Investment 2013-12-31 Add$0.32 - $2.04
($1.21)
$ 0.21-83%Add 16262.48%229,402
GCVRZWhitney Tilson 2013-09-30 Add0.1%$1.82 - $2.04
($1.9)
$ 0.21-89%Add 62.20%81,100
GCVRZMichael Price 2012-03-31 Add0.19%$1.25 - $1.37
($1.22)
$ 0.21-83%Add 29.41%4,400,000
GCVRZFirst Eagle Investment 2011-12-31 Reduce$0.89 - $1.34
($1.12)
$ 0.21-81%Reduce -99.53%1,402
GCVRZMichael Price 2011-09-30 Add0.26%$0.99 - $2.56
($1.4)
$ 0.21-85%Add 70.00%3,400,000
GCVRZFirst Eagle Investment 2011-09-30 Reduce-0.01%$0.99 - $2.56
($1.4)
$ 0.21-85%Reduce -81.30%301,402
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GCVRZ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GCVRZ: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about GCVRZ:

    News about GCVRZ:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Sanofi gets shot in the arm from dollar strength Feb 09 2016
    Europe close: Bank stocks lead losses again Feb 09 2016
    Europe open: Equity markets in the red as bank stocks weigh Feb 09 2016
    Europe midday: Stocks on the back foot as investors remain cautious Feb 08 2016
    EU drugs agency sets up Zika task force to speed vaccine work Feb 08 2016
    Quest for Zika vaccine widens; Africa, Asia deemed vulnerable Feb 02 2016
    France's Sanofi launches Zika virus vaccine research Feb 02 2016
    Sanofi launches hunt for Zika vaccine as disease fears grow Feb 02 2016
    Zika virus set to spread across Americas, spurring vaccine hunt Jan 25 2016
    New Redx director brings scientific, commercial expertise Jan 04 2016
    Philippines is first Asian country to approve dengue vaccine Dec 22 2015
    GlaxoSmithKline buys Bristol-Myers Squibb HIV assets for up to $1.46bn Dec 18 2015
    AstraZeneca buys majority stake in blood cancer specialist Acerta for £2.68bn Dec 17 2015
    Aspirin maker Bayer seeks to flex muscles in OTC sector Dec 16 2015
    AstraZeneca to buy Takeda's lung business for £383m Dec 16 2015
    Commodities stocks help European equities to end sharply higher Dec 15 2015
    Commodities stocks help European equities to bounce back Dec 15 2015
    Sanofi aims for top spot in consumer health via asset swap Dec 15 2015
    Drugs giants Sanofi and Boehringer Ingelheim in talks to exchange £13.2bn of assets Dec 15 2015
    European shares boosted by progress in Paris Dec 15 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)